Kenneth Ward Lyles, MD

Professor of Medicine
Senior Fellow in the Center for the Study of Aging and Human Development
Campus mail Duke Box 3881, Durham, NC 27710
Phone (919) 660-7520
Email address kenneth.lyles@duke.edu

My research activities focus on understanding ways that osteoporotic fractures affect people and trying to learn ways to reduce their impact on affected individuals and prevent further fractures. I have worked with patient with hip and vertebral fractures, gaining insight into the impairments such fractures cause. Also we have learned that a hip fracture is a major risk factor for subsequent fractures after the initial hip fracture. Our group completed a randomized, placebo-controlled trial that we designed with Novartis Pharmaceutical Corporation showing, that an annual infusion of a 5mg of the bisphosphonate zoledronic acid reduced subsequent fractures after a surgical procedure for a hip fracture by 35% when compared to a place infusion (New England Journal of Medicine, 11-1-07). In this study we also observed a 28% reduction in death in the zoledronic acid treated patients. Other research groups have shown that oral bisphosphonates also reduce mortality in patients with osteoporosis. Currently, we, with a number of collaborators, are conducting both animal and human studies to better understand this beneficial effect upon mortality.

In other work, our group tries to understand how other diseases such as strokes and spinal cord injury, and medications such as anticonvulsants place patients at risk for fractures. As we understand the epidemiology of these types of fractures, we plan to develop intervention trials to test whether we can reduce the occurrence of these fractures.

In addition to the above described work our group has help design and conduct a number of phase 1,2 and 3 clinical trials in Paget's disease of Bone and osteoporosis.

KEY WORDS:
Oteoporosis
Hip and vertebra fractures
Paget's disease of bone
Mobility impairments from metabolic bone diseases
Bisphosphonates

Education and Training

  • M.D., Virginia Commonwealth University, 1974

Publications

GRAHAM, SD, POULTON, SH, LINDER, J, WOODARD, BH, LYLES, KW, and PAULSON, DF. "ESTABLISHMENT OF A LONG-TERM ADENOCARCINOMA OF THE PROSTATE CELL-LINE IN THE NUDE-MOUSE." PROSTATE 7, no. 4 (1985): 369-376.

Full Text

Lyles, KW, Harrelson, JM, and Drezner, MK. "The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia." Journal of Clinical Endocrinology and Metabolism 54, no. 2 (1982): 307-315.

PMID
6976353
Scholars@Duke

Lyles, KW, Clark, AG, and Drezner, MK. "Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia." Calcified Tissue International 34, no. 1 (1982): 125-130.

PMID
6282408
Full Text

Lyles, KW, and Drezner, MK. "Parathyroid hormone effects on serum 1,25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: Evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity." Journal of Clinical Endocrinology and Metabolism 54, no. 3 (1982): 638-644.

PMID
6276432
Scholars@Duke

Sutton, GP, Lyles, KW, and Wiebe, RH. "Steroid secretion and testosterone binding in a woman with an ovarian hilus cell tumor and thyrotoxicosis." American Journal of Obstetrics and Gynecology 141, no. 5 (1981): 535-538.

PMID
7197469
Scholars@Duke

Lyles, KW, and Drezner, MK. "An overview of calcium homeostasis in humans." Urologic Clinics of North America 8, no. 2 (1981): 209-226.

PMID
7022986
Scholars@Duke

Drezner, MK, Lyles, KW, Haussler, MR, and Harrelson, JM. "Evaluation of a role of 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia." Journal of Clinical Investigation 66, no. 5 (1980): 1020-1032.

PMID
6253520
Full Text

Lyles, KW, Berry, WR, and Haussler, M. "Hypophosphatemia osteomalacia: Association with prostatic carcinoma." Annals of Internal Medicine 93, no. 2 (1980): 275-278.

PMID
7406380
Scholars@Duke

Drezner, MK, Haussler, MR, Lyles, KW, and Harrelson, JM. "The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH)." Clinical Research 27, no. 2 (1979): 365A-.

Scholars@Duke

Lyles, KW, Colón-Emeric, CS, Magaziner, JS, Adachi, JD, Pieper, CF, Mautalen, C, Hyldstrup, L, Recknor, C, Nordsletten, L, Moore, KA, Lavecchia, C, Zhang, J, Mesenbrink, P, Hodgson, PK, Abrams, K, Orloff, JJ, Horowitz, Z, Eriksen, EF, Boonen, S, and HORIZON Recurrent Fracture Trial, . "Zoledronic acid and clinical fractures and mortality after hip fracture." N Engl J Med 357, no. 18: 1799-1809.

PMID
17878149
Full Text

Pages